Alnylam begins global Phase 3 trial dosing of zilebesiran

Alnylam has dosed the first patient in ZENITH, its global Phase 3 cardiovascular outcomes trial of the investigational therapy zilebesiran for patients with uncontrolled hypertension, the company said. The trial—which is being conducted in collaboration with Roche—will enroll about 11,000 patients across 35 countries. It will compare twice-annual 300 mg subcutaneous doses of zilebesiran versus […] The post Alnylam begins global Phase 3 trial dosing of zilebesiran appeared first on Longevity.Technology.